ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Double-antigen sandwich ELISA based on chimeric antigens for detection of antibodies to Trypanosoma cruzi in human sera - A phase II study.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeLaboratory confirmation of chronic Chagas disease (CD) relies on serology, yet conventional indirect ELISAs depend on species- and class-specific secondary antibodies and remain prone to cross-reactivity. The chimeric antigens IBMP-8.1, IBMP-8.2, IBMP-8.3, and IBMP-8.4 perform well in indirect formats, and a proof-of-concept phase I double-antigen sandwich ELISA (DAgS-ELISA) achieved high specificity but limited sensitivity. We re-optimized and validated the IBMP-DAgS-ELISA in a phase II study.
methodsThe four antigens were conjugated to horseradish peroxidase and re-optimized by checkerboard titration. Diagnostic performance was assessed against a latent class analysis reference standard using 403 T. cruzi-positive and 399 T. cruzi-negative sera from the Central Public Health Laboratory of Bahia, applying a single pre-specified reactivity-index cut-off (RI ≥ 1.0). Cross-reactivity was evaluated in 206 sera from individuals with other infectious diseases, and intra-plate repeatability in 28 positive and 28 negative sera tested in triplicate.
resultsIBMP-8.4 showed the highest values for most performance measures (area under the curve 99.8%, sensitivity 99.8%, specificity 98.0%, accuracy 98.9%, diagnostic odds ratio 19,648, Cohen's κ 0.98), and IBMP-8.3 the highest specificity (99.0%). The parallel combination IBMP-8.3/IBMP-8.4 reached 100% sensitivity and 97.0% specificity. Cross-reactivity was low overall and absent for IBMP-8.4 (0/206), including against Leishmania and Schistosoma spp. Across triplicate testing, sensitivity (92.9-100%) and area under the curve (94.3-100%) were stable for all antigens, whereas specificity varied more widely (78.6-100%) in the repeatability subset.
conclusionThe re-optimized IBMP-DAgS-ELISA matches the indirect-ELISA benchmark of the same antigens while detecting total antibodies independently of immunoglobulin class or host species. IBMP-8.4, alone or combined with IBMP-8.3, is an accurate option for chronic CD serology and reinstates a double-antigen sandwich platform on a fully defined chimeric-antigen basis.
Indexed as
Identifiers
42806187What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.